Back

Cost implications of misunderstanding statin intolerance.

29 August 2017 (13:25 - 13:40)
Organised by:
Congress Presentation Part of: Are we prepared to reduce LDL-cholesterol at any cost? Drug therapy Open Access ESC Congress 2017

About the speaker

Photo
Professor Erik Stroes

AmsterdamUMC location AMC, Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Challenges for reaching LDL-C goals in high and very high risk patients.
Professor L. Tokgozoglu (Ankara, TR)
Presentation thumbnail
High potency statins and beyond: benefits of combination therapy.
Doctor M. Farnier (Dijon, FR)
Presentation thumbnail
Last step on the ladder: proprotein convertase subtilisin/kexin type 9 (PCSK9).
Professor L. Tokgozoglu (Ankara, TR)
Presentation thumbnail
Conclusion - Are we prepared to reduce LDL-cholesterol at any cost?
Professor L. Tokgozoglu (Ankara, TR)

Access the full session

Session thumbnail
Are we prepared to reduce LDL-cholesterol at any cost?

The Event

Event poster

ESC Congress 2017

29 August 2017 13:25 CET
You may be interested in
thumbnail
Congress Presentation
Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel.
31 August 2019
thumbnail
Webinar
Reducing risk in the post-MI patient
6 September 2023
thumbnail
Congress Presentation
Cost impact of the ESC/EAS 2019 dyslipidemia guidelines recommended use of PSCK9i in very-high-risk patients with an LDL <1.8mmol/L for secondary prevention
26 August 2023
thumbnail
Congress Presentation
Forging the path: strategic combinations to achieve lipid targets
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources